Modified Medical Gauze Helps Reduce the Risk of Infection (MIS-278)
PITTSBURGH, Jan. 18, 2017 /PRNewswire/ -- An inventor and registered nurse from Brooklyn Park, Minn., works in the homecare field, and she's astonished this hasn't been created yet. "I've had clients who've ended up with cellulitis and required antibiotics, which Americans are becoming resistant to," she said, "That's why I've come up with this modified gauze."
BACITRACIN GAUZE enhances the healing process for a wound victim. It helps protect against infection, as well as reduces or eliminates the need for strong oral antibiotics. Overall, it promotes good health and peace of mind.
Ergonomic, easy to use and producible in design variations, BACITRACIN GAUZE is ideal for home healthcare services, hospitals, clinics, doctors' offices, etc.
The original design was submitted to the Minneapolis office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 16-MIS-278, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com - https://www.youtube.com/user/inventhelp
Acadia Pharmaceuticals Inc. today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 8,...
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May...
BeiGene, Ltd. , a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024....
Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics.
This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin...
Arrowhead Pharmaceuticals, Inc. today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.
Webcast and Conference Call and...
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of...
